Many patients require intensive insulin therapy (multiple daily injections or continuous subcutaneous insulin infusion) to achieve optimal glycemic control, putting these patients at high risk for hypoglycemia and severe hypoglycemia¶¶17.
At this time, FreeStyle Libre 3 is not currently eligible for Medicare reimbursement, and Medicaid eligibility may vary by state.
Medicare coverage is available for the FreeStyle Libre 2 system if the FreeStyle Libre 2 reader is used to review glucose data on some days every month. Medicare and other third party payor criteria apply.
Abbott provides this information as a courtesy, it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors.
FreeStyle Libre 2 and FreeStyle Libre 3 systems are indicated for use in people with diabetes age 4 and older.
The FreeStyle Libre 14 day system is indicated for use in people with diabetes age 18 and older.
* Participating pharmacies are subject to change without notice. Product availability may vary by retailer.
† The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Use of the FreeStyle Libre 3 app requires registration with LibreView.
‡ Among patient-applied sensors.
§ The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Use of the FreeStyle Libre 2 app requires registration with LibreView.
|| The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.
¶ Notifications will only be received when alarms are turned on and the sensor is within 20 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 2 User’s Manual for more information.
# The user's device must have internet connectivity for glucose data to automatically upload to LibreView and to transfer to connected LibreLinkUp app users.
** The LibreLinkUp app is only compatible with certain mobile devices and operating systems. Please check http://www.librelinkup.com for more information about device compatibility before using the app. Use of the LibreLinkUp app requires registration with LibreView. LibreLinkUp is not intended to be used for dosing decisions. The user should follow instructions on the continuous glucose monitoring system. LibreLinkUp is not intended to replace self-monitoring practices as advised by a physician.
†† The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.
‡‡ Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore the study data is applicable to both products.
§§ Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore the study data is applicable to both products.
|||| Includes ambulance visits, ED visits, and hospitalizations (29.3% rate of ambulance attendance per severe hypoglycemic event14; $214.47 per ambulance attendance, updated to $232 per medical care CPI15; 17% rate of ED visit per severe hypoglycemic event16; $1387 per ED visit and $17,564 per hospitalization, updated to $1645 and $20,840 per medical care CPI, respectively17).
¶¶ Severe hypoglycemic events are defined by events requiring external third-party assistance, or leading to coma or convulsion.
## Based on a comparison of list prices of the FreeStyle Libre 2 system versus competitors’ CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
*** Data based on the number of patients assigned to each manufacturer based on last filled prescription in US Retail Pharmacy and DME.
††† Based on a comparison of list prices of the FreeStyle Libre 2 system versus competitors’ CGM systems, assuming annual use of one receiver (or equivalent hardware) and quantity of transmitters and/or sensors according to use life.
References: 1. Data on file, Abbott Diabetes Care. 2. FreeStyle Libre 2 AMCP Dossier. 3. Charleer S, et al. Diabetes Care (2020): https://doi.org/10.2337/dc19-1610 4. Fokkert, M. BMJ Open Diabetes Res Care (2019): https://doi.org/10.1136/bmjdrc-2019-000809 5. Bergenstal, R. J Endocr Soc (2021): https://doi.org/10.1210/jendso/bvab013 6. Bolinder, J. The Lancet (2016): https://doi.org/10.1016/s0140-6736(16)31535-5 7. Haak, T. Diabetes Ther (2017): https://doi.org/10.1007/s13300-016-0223-6 8. Miller E, et al. AJMC (2021): https://doi.org/10.37765/ajmc.2021.88780 9. Kerr M, et al. Poster presented at the ATTD Conference, Madrid, Spain, February 19-22, 2020. https://doi.org/10.1089/dia.2020.2525.abstracts 10. Deshmukh, H. Diabetes Care (2020): https://doi.org/10.2337/dc20-0738 11. ADA. Diabetes Care (2018): https://doi.org/10.2337/dci18-0007 12. DCCT Research Group. N Engl J Med 329, no. 14 (1993): https://doi.org/10.1056/NEJM199309303291401 13. Heller, SR. Diabetic Med (2015): https://doi.org/10.1111/dme.12844 14. Foos, V. J Med Econ (2015): https://doi.org/10.3111/13696998.2015.1006730 15. Bullano, MF. Am J Health Syst Pharm (2006): https://doi.org/10.2146/ajhp050552 16. Quilliam, BJ. Am J Manag Care (2011): https://doi.org/10.1016/j.clinthera.2011.09.020 17. DCCT Research Group. Am J Med 90, no. 1 (1991): https://doi.org/10.1016/0002-9343(91)90605-w 18. Campbell, F. Pediatr Diabetes (2018): https://doi.org/10.1111/pedi.12735 19. Tyndall, V. Diabetologia (2019): https://doi.org/10.1007/s00125-019-4894-1 20. Evans M, et al. Diabetes Therapy (2022): https://doi.org/10.1007/s13300-022-01253-9 21. Wright, E. Diabetes Spectrum (2021): https://doi.org/10.2337/ds20-0069 22. Kroger, J. Diabetes Therapy (2020): https://doi.org/10.1007/s13300-019-00741-9 23. Carlson AL, et al. BMJ Open Diabetes Res Care (2022): https://doi.org/10.1136/bmjdrc-2021-002590 24. Calliari, L. Diabetology Metab Syndr (2020): https://doi.org/10.1186/s13098-019-0513-z 25. Ogawa, W. Poster presented at: American Diabetes Association 81st Scientific Session, Virtual, June 25-29, 2021. https://doi.org/10.2337/db21-607-P 26. Dunn, T. Diabetes Res Clin Prac (2018): https://doi.org/10.1016/j.diabres.2017.12.015 27. Lang, J. Diabetes (2019): https://doi.org/10.2337/db19-972-p 28. Miller E, et al. Am J Med Open (2022): https://doi.org/10.1016/j.ajmo.2022.100008
ADC-17128 v11.0 10/22
Payer.freestylelibre.us/en is a product-specific website intended only for residents of the United States.
If you are a resident of another country, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.
ADC-21099 v3.0 07/21